Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $44.00.

A number of research analysts recently issued reports on the company. Mizuho set a $45.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th. Guggenheim reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research note on Monday, May 4th. Finally, Wall Street Zen cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th.

Hedge Funds Weigh In On Assembly Biosciences

Hedge funds have recently modified their holdings of the stock. Informed Momentum Co LLC boosted its position in shares of Assembly Biosciences by 1.6% in the 4th quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock valued at $1,004,000 after purchasing an additional 451 shares during the period. ADAR1 Capital Management LLC boosted its position in shares of Assembly Biosciences by 4.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 800 shares during the period. Geode Capital Management LLC boosted its position in shares of Assembly Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock valued at $4,468,000 after purchasing an additional 1,212 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Assembly Biosciences by 4.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock valued at $1,095,000 after purchasing an additional 1,634 shares during the period. Finally, Palumbo Wealth Management LLC boosted its position in shares of Assembly Biosciences by 7.2% in the 4th quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock valued at $1,269,000 after purchasing an additional 2,507 shares during the period. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Trading Down 5.3%

Assembly Biosciences stock opened at $24.26 on Friday. The stock has a market cap of $385.49 million, a price-to-earnings ratio of -220.53 and a beta of 1.07. The company’s 50-day moving average price is $26.83 and its two-hundred day moving average price is $28.73. Assembly Biosciences has a 52 week low of $16.81 and a 52 week high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.11. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%.The company had revenue of $8.21 million for the quarter, compared to analysts’ expectations of $9.27 million. Research analysts expect that Assembly Biosciences will post 1.9 earnings per share for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.